Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples